Table 1.

Patient and donor demographics and allograft characteristics

Characteristic	Value
Age in years, median (range)	64 (35-74)
Gender, N (%)
Female	7 (32)
Male	15 (68)
Conditioning, N (%)
Flu/Mel100/TBI	15 (68)
Flu/Mel100/Thiotepa	7 (32)
Diagnosis N (%)
AML / MDS	16 (73)
CML / MPD	4 (18)
CLL	1 (5)
Aplastic Anemia	1 (5)
Disease Status, N (%)
PIF	7 (32)
CR1	6 (27)
CR2 / CP2	4 (18)
Other	5 (23)
Cytogenetic Risk, N (%)
Good	2 (9)
Intermediate	10 (45)
Bad	5 (23)
Unknown	5 (23)
Cell Source, N (%)
Peripheral blood	3 (14)
Bone marrow	19 (86)
HCT-CI, median (range)	2 (0-8)

Legends: Flu – fludarabine; Mel – melphalan; TBI – total body irradiation; AML – acute myeloid leukemia; MDS – myelodysplastic syndrome; CML – chronic myeloid leukemia; MPD – myeloproliferative disorder; CLL – chronic lymphocytic leukemia; PIF – primary induction failure; CR1 – first complete remission; CR2 – second complete remission; Cytogenetics according to Southwestern Oncology Group cytogenetics risk category; HCT-CI – hematopoietic stem cell transplant comorbidity index